Cargando…

Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations

OBJECTIVE: To determine the efficacy of fibroblast growth factor‐2 (FGF‐2) in treating chronic nonhealing tympanic membrane (TM) perforations. METHOD: Double‐blinded, randomized placebo controlled phase 2 clinical trial for patients with chronic TM perforations of more than 3 months duration with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Felipe, Shu, Edina, Lee, Daniel J., Jung, David H., Quesnel, Alicia M., Stankovic, Konstantina M., Abdul‐Aziz, Dunia E., Bay, Camden P., Quinkert, Amy, Welling, D. Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444771/
https://www.ncbi.nlm.nih.gov/pubmed/32864435
http://dx.doi.org/10.1002/lio2.395
_version_ 1783573863880196096
author Santos, Felipe
Shu, Edina
Lee, Daniel J.
Jung, David H.
Quesnel, Alicia M.
Stankovic, Konstantina M.
Abdul‐Aziz, Dunia E.
Bay, Camden P.
Quinkert, Amy
Welling, D. Bradley
author_facet Santos, Felipe
Shu, Edina
Lee, Daniel J.
Jung, David H.
Quesnel, Alicia M.
Stankovic, Konstantina M.
Abdul‐Aziz, Dunia E.
Bay, Camden P.
Quinkert, Amy
Welling, D. Bradley
author_sort Santos, Felipe
collection PubMed
description OBJECTIVE: To determine the efficacy of fibroblast growth factor‐2 (FGF‐2) in treating chronic nonhealing tympanic membrane (TM) perforations. METHOD: Double‐blinded, randomized placebo controlled phase 2 clinical trial for patients with chronic TM perforations of more than 3 months duration with a cross‐over arm. Patients received either FGF‐2 or placebo (sterile water) saturated gelatin sponge in the perforation after rimming the perforation under topical anesthesia. The perforation was then covered with Tisseel fibrin glue. The primary endpoint was complete closure of the TM perforation. Secondary end points included change in hearing and partial TM closure rates. The TM was examined every 3 weeks with otoendoscopy for closure. The treatment was repeated if there was incomplete closure every 3 weeks up to a total of three treatments per arm. RESULTS: Seventy four patients were recruited for the study. Fifty seven met eligibility criteria and fifty four completed the study. Ten of 14 perforations closed completely in the placebo group (71.4%) and 23 of 40 perforations closed completely in the FGF‐2 treatment group (57.5%), P value = .36. Pure tone averages and word recognition scores were not statistically significantly different between study groups post‐treatment. After initial complete closure, re‐perforation occurred in seven FGF‐2 treated patients and two placebo patients making the effective final closure rate 40% for FGF and 57% for placebo, respectively. CONCLUSION: No statistically significant difference in tympanic membrane perforation closure rate was found between the FGF‐2 and placebo groups. There were no differences in hearing outcomes between the groups. LEVEL OF EVIDENCE: 1b.
format Online
Article
Text
id pubmed-7444771
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-74447712020-08-28 Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations Santos, Felipe Shu, Edina Lee, Daniel J. Jung, David H. Quesnel, Alicia M. Stankovic, Konstantina M. Abdul‐Aziz, Dunia E. Bay, Camden P. Quinkert, Amy Welling, D. Bradley Laryngoscope Investig Otolaryngol Comprehensive (General) Otolaryngology OBJECTIVE: To determine the efficacy of fibroblast growth factor‐2 (FGF‐2) in treating chronic nonhealing tympanic membrane (TM) perforations. METHOD: Double‐blinded, randomized placebo controlled phase 2 clinical trial for patients with chronic TM perforations of more than 3 months duration with a cross‐over arm. Patients received either FGF‐2 or placebo (sterile water) saturated gelatin sponge in the perforation after rimming the perforation under topical anesthesia. The perforation was then covered with Tisseel fibrin glue. The primary endpoint was complete closure of the TM perforation. Secondary end points included change in hearing and partial TM closure rates. The TM was examined every 3 weeks with otoendoscopy for closure. The treatment was repeated if there was incomplete closure every 3 weeks up to a total of three treatments per arm. RESULTS: Seventy four patients were recruited for the study. Fifty seven met eligibility criteria and fifty four completed the study. Ten of 14 perforations closed completely in the placebo group (71.4%) and 23 of 40 perforations closed completely in the FGF‐2 treatment group (57.5%), P value = .36. Pure tone averages and word recognition scores were not statistically significantly different between study groups post‐treatment. After initial complete closure, re‐perforation occurred in seven FGF‐2 treated patients and two placebo patients making the effective final closure rate 40% for FGF and 57% for placebo, respectively. CONCLUSION: No statistically significant difference in tympanic membrane perforation closure rate was found between the FGF‐2 and placebo groups. There were no differences in hearing outcomes between the groups. LEVEL OF EVIDENCE: 1b. John Wiley & Sons, Inc. 2020-05-14 /pmc/articles/PMC7444771/ /pubmed/32864435 http://dx.doi.org/10.1002/lio2.395 Text en © 2020 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals, Inc. on behalf of The Triological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Comprehensive (General) Otolaryngology
Santos, Felipe
Shu, Edina
Lee, Daniel J.
Jung, David H.
Quesnel, Alicia M.
Stankovic, Konstantina M.
Abdul‐Aziz, Dunia E.
Bay, Camden P.
Quinkert, Amy
Welling, D. Bradley
Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations
title Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations
title_full Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations
title_fullStr Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations
title_full_unstemmed Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations
title_short Topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations
title_sort topical fibroblast growth factor‐2 for treatment of chronic tympanic membrane perforations
topic Comprehensive (General) Otolaryngology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444771/
https://www.ncbi.nlm.nih.gov/pubmed/32864435
http://dx.doi.org/10.1002/lio2.395
work_keys_str_mv AT santosfelipe topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT shuedina topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT leedanielj topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT jungdavidh topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT quesnelaliciam topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT stankovickonstantinam topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT abdulazizduniae topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT baycamdenp topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT quinkertamy topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations
AT wellingdbradley topicalfibroblastgrowthfactor2fortreatmentofchronictympanicmembraneperforations